U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H19N3O.CH4O3S
Molecular Weight 377.458
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PHENTOLAMINE MESYLATE

SMILES

CS(O)(=O)=O.CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC=CC(O)=C3

InChI

InChIKey=OGIYDFVHFQEFKQ-UHFFFAOYSA-N
InChI=1S/C17H19N3O.CH4O3S/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15;1-5(2,3)4/h2-8,11,21H,9-10,12H2,1H3,(H,18,19);1H3,(H,2,3,4)

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00692 | https://www.drugs.com/pro/phentolamine.html | http://reference.medscape.com/drug/regitine-oraverse-phentolamine-342392 | https://www.ncbi.nlm.nih.gov/pubmed/26180030

Phentolamine (trade name Regitine) is a reversible nonselective α-adrenergic antagonist used for the control of hypertensive emergencies, most notably due to pheochromocytoma. Phentolamine produces its therapeutic actions by competitively blocking alpha-adrenergic receptors (primarily excitatory responses of smooth muscle and exocrine glands), leading to a muscle relaxation and a widening of the blood vessels. This widening of the blood vessels results in a lowering of blood pressure. The action of phentolamine on the alpha-adrenergic receptors is relatively transient and the blocking effect is incomplete. The drug is more effective in antagonizing responses to circulating epinephrine and/or norepinephrine than in antagonizing responses to mediator released at the adrenergic nerve ending. Phentolamine also stimulates β-adrenergic receptors and produces a positive inotropic and chronotropic effect on the heart and increases cardiac output. Phentolamine is indicated for the prevention or control of hypertensive episodes that may occur in a patient with pheochromocytoma as a result of stress or manipulation during preoperative preparation and surgical excision. Phentolamine is indicated for the prevention or treatment of dermal necrosis and sloughing following intravenous administration or extravasation of norepinephrine. Phentolamine is also indicated for the diagnosis of pheochromocytoma by the Phentolamine blocking test. Acute and prolonged hypotensive episodes, tachycardia, and cardiac arrhythmias have been reported. In addition, weakness, dizziness, flushing, orthostatic hypotension, nasal stuffiness, nausea, vomiting, and diarrhea may occur.

Originator

Tappi, G.|Forni, P.V.
3
Sources: Annali di Chimica Applicata (1948), 38, 602-13.

Approval Year

1952
114
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
 3.7 nM [Kd]
Antagonist
2849
 16.6 nM [Kd]
Antagonist
2849
 5.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
REGITINE

Approved Use

Phentolamine Mesylate for Injection is indicated for the prevention or control of hypertensive episodes that may occur in a patient with pheochromocytoma as a result of stress or manipulation during preoperative preparation and surgical excision. Phentolamine Mesylate for Injection is indicated for the prevention or treatment of dermal necrosis and sloughing following intravenous administration or extravasation of norepinephrine. Phentolamine Mesylate for Injection is also indicated for the diagnosis of pheochromocytoma by the phentolamine blocking test.

Launch Date

1952
Primary
Approved
8583
REGITINE

Approved Use

Phentolamine Mesylate for Injection is indicated for the prevention or control of hypertensive episodes that may occur in a patient with pheochromocytoma as a result of stress or manipulation during preoperative preparation and surgical excision. Phentolamine Mesylate for Injection is indicated for the prevention or treatment of dermal necrosis and sloughing following intravenous administration or extravasation of norepinephrine. Phentolamine Mesylate for Injection is also indicated for the diagnosis of pheochromocytoma by the phentolamine blocking test.

Launch Date

1952
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
67.05 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/24452521
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENTOLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
197.59 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/24452521
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENTOLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.32 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/24452521
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENTOLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
unhealthy, 26–83
Health Status: unhealthy
Age Group: 26–83
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Disc. AE: Rhinitis, Vomiting...
AEs leading to
discontinuation/dose reduction:
Rhinitis
Vomiting
Nausea
Diarrhea
Headache
Dizziness
Tachycardia
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
unhealthy, 28–80
Health Status: unhealthy
Age Group: 28–80
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Disc. AE: Dyspnea, Tachycardia...
AEs leading to
discontinuation/dose reduction:
Dyspnea (0.84%)
Tachycardia (0.84%)
Epistaxis (0.84%)
Cephalgia (0.84%)
Flushing (serious, 0.84%)
Chest pain (serious, 0.84%)
Shortness of breath (serious, 0.84%)
Tachycardia (serious, 0.84%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
5 mg single, intravenous|intramuscular
Recommended
Dose: 5 mg
Route: intravenous|intramuscular
Route: single
Dose: 5 mg
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
unhealthy
Health Status: unhealthy
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
Disc. AE: Myocardial infarction, Cerebrovascular spasm...
AEs leading to
discontinuation/dose reduction:
Myocardial infarction
Cerebrovascular spasm
Cerebral vascular occlusion
Hypotension
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
AEs

AEs

AESignificanceDosePopulation
Diarrhea Disc. AE
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
unhealthy, 26–83
Health Status: unhealthy
Age Group: 26–83
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Dizziness Disc. AE
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
unhealthy, 26–83
Health Status: unhealthy
Age Group: 26–83
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Headache Disc. AE
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
unhealthy, 26–83
Health Status: unhealthy
Age Group: 26–83
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Nausea Disc. AE
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
unhealthy, 26–83
Health Status: unhealthy
Age Group: 26–83
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Rhinitis Disc. AE
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
unhealthy, 26–83
Health Status: unhealthy
Age Group: 26–83
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Tachycardia Disc. AE
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
unhealthy, 26–83
Health Status: unhealthy
Age Group: 26–83
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Vomiting Disc. AE
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
unhealthy, 26–83
Health Status: unhealthy
Age Group: 26–83
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Cephalgia 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
unhealthy, 28–80
Health Status: unhealthy
Age Group: 28–80
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Dyspnea 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
unhealthy, 28–80
Health Status: unhealthy
Age Group: 28–80
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Epistaxis 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
unhealthy, 28–80
Health Status: unhealthy
Age Group: 28–80
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Tachycardia 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
unhealthy, 28–80
Health Status: unhealthy
Age Group: 28–80
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Chest pain serious, 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
unhealthy, 28–80
Health Status: unhealthy
Age Group: 28–80
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Flushing serious, 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
unhealthy, 28–80
Health Status: unhealthy
Age Group: 28–80
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Shortness of breath serious, 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
unhealthy, 28–80
Health Status: unhealthy
Age Group: 28–80
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Tachycardia serious, 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
unhealthy, 28–80
Health Status: unhealthy
Age Group: 28–80
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Cerebral vascular occlusion Disc. AE
5 mg single, intravenous|intramuscular
Recommended
Dose: 5 mg
Route: intravenous|intramuscular
Route: single
Dose: 5 mg
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
unhealthy
Health Status: unhealthy
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
Cerebrovascular spasm Disc. AE
5 mg single, intravenous|intramuscular
Recommended
Dose: 5 mg
Route: intravenous|intramuscular
Route: single
Dose: 5 mg
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
unhealthy
Health Status: unhealthy
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
Hypotension Disc. AE
5 mg single, intravenous|intramuscular
Recommended
Dose: 5 mg
Route: intravenous|intramuscular
Route: single
Dose: 5 mg
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
unhealthy
Health Status: unhealthy
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
Myocardial infarction Disc. AE
5 mg single, intravenous|intramuscular
Recommended
Dose: 5 mg
Route: intravenous|intramuscular
Route: single
Dose: 5 mg
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
unhealthy
Health Status: unhealthy
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:8081
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8081
ChemicalBook
CB6665216
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6665216
eMolecules
31790003
https://www.emolecules.com/cgi-bin/more?vid=31790003
eMolecules
975745
https://www.emolecules.com/cgi-bin/more?vid=975745
MolPort
MolPort-000-771-097
https://www.molport.com/shop/molecule-link/MolPort-000-771-097
MolPort
MolPort-001-783-569
https://www.molport.com/shop/molecule-link/MolPort-001-783-569
ZINC
ZINC000000020251
http://zinc15.docking.org/substances/ZINC000000020251
PubMed

PubMed

TitleDatePubMed
Comparative pathophysiology, toxicology, and human cancer risk assessment of pharmaceutical-induced hibernoma.
2013-12-15
Neural mechanism of pressor action of nitric oxide synthase inhibitor in anesthetized monkeys.
1996-09
Cocaine-associated myocardial infarction.
1996-08
Contribution of peripheral alpha 1A-adrenoceptors to pain induced by formalin or by alpha-methyl-5-hydroxytryptamine plus noradrenaline.
1996-04-22
KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
1995-08
Effects of chronic NO synthase inhibition in rats on renin-angiotensin system and sympathetic nervous system.
1995-06
Involvement of the sympathetic postganglionic neuron in capsaicin-induced secondary hyperalgesia in the rat.
1995-03
Reasons for high drop-out rate with self-injection therapy for impotence.
1994-09
Further characterization of human alpha 2-adrenoceptor subtypes: [3H]RX821002 binding and definition of additional selective drugs.
1994-01-24
Comparison of a mixture of papaverine, phentolamine and prostaglandin E1 with other intracavernous injections.
1994
The involvement of noradrenaline, 5-hydroxytryptamine and acetylcholine in imipramine-induced seizures in mice.
1993-10-15
Presynaptic alpha 2-autoreceptors in brain cortex: alpha 2D in the rat and alpha 2A in the rabbit.
1993-07
Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.
1993-05
Treatment of peripheral ischemia secondary to lidocaine containing epinephrine.
1989-07
Complications of phenylpropanolamine.
1989-04
Propranolol antagonizes hypotension induced by alpha-blockers but not by sodium nitroprusside or methacholine.
1989-02
Prostaglandins inhibit endogenous pain control mechanisms by blocking transmission at spinal noradrenergic synapses.
1988-04
Involvement of beta 2-adrenoceptor-mediated mechanisms in the cardiovascular responses to alpha 1- and alpha 2-adrenoceptor antagonism in conscious, unrestrained, Long Evans and Brattleboro rats.
1988-01
Antagonism of cocaine-induced hepatotoxicity by the alpha adrenergic antagonists phentolamine and yohimbine.
1987-08
Cardiac myonecrosis in hypertensive crisis associated with monoamine oxidase inhibitor therapy.
1987-05
Sympathetic mechanisms in poststenotic myocardial ischemia.
1986
Hypertension after epidural meperidine.
1985-11
Ventricular tachycardia induced by clonidine withdrawal.
1985-06
Dissociation of epinephrine's hyperglycemic and anorectic effect.
1985-03
[Hemodynamic and respiratory effects of phentolamine in pulmonary hypertension secondary to chronic obstructive syndrome].
1985-01-19
Pharmacological, hemodynamic and autonomic nervous system mechanisms responsible for the blood pressure and heart rate lowering effects of pergolide in rats.
1984-03
Involvement of adenosine receptor activities in aggressive responses produced by clonidine in mice.
1984
A nonhuman primate model for evaluating the potential of antihypertensive drugs to cause orthostatic hypotension.
1983-05
Contribution of alpha-adrenoceptor activation to the pathogenesis of norepinephrine cardiomyopathy.
1983-04
Role of autonomic nervous system in the pathogenesis of angina pectoris.
1983-02
Some functional changes in experimentally induced cardiac overload.
1983
The effects of cigarette smoke and nicotine on platelet thrombus formation in stenosed dog coronary arteries: inhibition with phentolamine.
1982-03
[Acute and chronic cardiac decompensation: is vasodilator therapy useful?].
1982-01-14
Alpha-adrenoceptor blockade by phentolamine causes beta-adrenergic vasodilation by increased catecholamine release due to presynaptic alpha-blockade.
1982-01-01
Mediation of renin release in essential hypertension by alpha-adrenoreceptors.
1981-11-01
Hypertensive crisis resulting from avocados and a MAO inhibitor.
1981-11
Pharmacological characterisation of the alpha-adrenoceptors responsible for a decrease of blood pressure in the nucleus tractus solitarii of the rat.
1981-09
Noninvasive assessment of load reduction in chronic congestive heart failure patients.
1981-08
Effects of clonidine on canine cardiac neuroeffector structures controlling heart rate.
1980-10
Electrophysiologic properties of hydralazine in man.
1980-09
Noradrenergic influences on sound-induced seizures.
1980-08
Effects of pretreatment with 6-hydroxydopamine or noradrenergic receptor blockers on the clonidine-induced distruption of conditioned avoidance responding.
1979-09-01
Chronic treatment with antidepressant drugs: potentiation of apomorphine-induced aggressive behaviour in rats.
1979-08
Oral therapy with phentolamine in chronic congestive heart failure.
1979-04
DDT-induced myoclonus: serotonin and alpha noradrenergic interaction.
1979-02
Three cases of sinoatrial block induced by anticonvulsants.
1978-07
A study of the sympathomimetic action of guanethidine on the isolated anococcygeus muscle of the rat.
1978-02
Effects of phentolamine, dihydroergocristine and isoxsuprine on the blood pressure and heart rate in normotensive, hypotensive and hypertensive rats.
1975
Use of phentolamine in acute myocardial infarction associated with hypertension and left ventricular failure.
1973-04
Positive phentolamine test in hypertension induced by a nasal decongestant.
1969-04-17
Patents

Patents

CH262433
3

Sample Use Guides

In Vivo Use Guide
Prevention or control of hypertensive episodes in the patient with pheochromo-cytoma. For preoperative reduction of elevated blood pressure, 5 mg of Phentolamine mesylate (1 mg for children) is injected intravenously or intramuscularly 1 or 2 hours before surgery, and repeated if necessary. During surgery, Phentolamine mesylate (5 mg for adults, 1 mg for children) is administered intravenously as indicated, to help prevent or control paroxysms of hypertension, tachycardia, respiratory depression, convulsions, or other effects of epinephrine intoxication.
Route of Administration: Other
In Vitro Use Guide
Cancer cell lines, PC-3, DU-145, NCI/ADR-RES, and SKOV3 were used for activity evaluation. Cells were seeded in 96-well plates. After 24 hr, cells were fixed with 10% trichloroacetic acid (TCA) representing cell population at time zero (T0). After additional incubation of 0.1% DMSO or phentolamine for 48 hr, cells were fixed with 10% TCA and SRB at 0.4% (w/v) in 1% acetic acid was added to stain cells. Unbound SRB was washed out. SRB bound cells were solubilized with 10mM Trizma base.
Name Type Language
PHENTOLAMINE MESILATE
EP   JAN   MART.   WHO-DD  
Preferred Name English
PHENTOLAMINE MESYLATE
ORANGE BOOK   USP   USP-RS   VANDF  
Common Name English
REGITINE
Brand Name English
RYZUMVI
Brand Name English
ORAVERSE
Brand Name English
M-(N-(2-IMIDAZOLIN-2-YLMETHYL)-P-TOLUIDINO)PHENOL MONOMETHANESULFONATE (SALT)
Common Name English
PHENTOLAMINE MESYLATE [USP-RS]
Common Name English
PHENTOLAMINE METHANESULFONATE [MI]
Common Name English
PHENTOLAMINE MESYLATE [USP MONOGRAPH]
Common Name English
PHENOL, 3-(((4,5-DIHYDRO-1H-IMIDAZOL-2-YL)METHYL)(4-METHYLPHENYL)AMINO)-, MONOMETHANESULPHONATE (SALT)
Common Name English
MESYLATE PHENTOLAMINE
Common Name English
PHENOL, 3-(((4,5-DIHYDRO-1H-IMIDAZOL-2-YL)METHYL)(4-METHYLPHENYL)AMINO)-, MONOMETHANESULFONATE (SALT)
Common Name English
M-(N-(2-IMIDAZOLIN-2-YLMETHYL)-P-TOLUIDINO)PHENOL MONOMETHANESULPHONATE (SALT)
Common Name English
Phentolamine mesilate [WHO-DD]
Common Name English
PHENTOLAMINE MESILATE [MART.]
Common Name English
PHENTOLAMINE MESYLATE [VANDF]
Common Name English
PHENTOLAMINE MESYLATE [ORANGE BOOK]
Common Name English
PHENTOLAMINE MESILATE [JAN]
Common Name English
PHENTOLAMINE MESILATE [EP MONOGRAPH]
Common Name English
PHENTOLAMINE METHANESULFONATE
MI  
Common Name English
NV-101
Code English
Classification Tree Code System Code
NCI_THESAURUS C29713
Created by admin on Mon Mar 31 17:47:32 GMT 2025 , Edited by admin on Mon Mar 31 17:47:32 GMT 2025
Code System Code Type Description
SMS_ID
100000091550
Created by admin on Mon Mar 31 17:47:32 GMT 2025 , Edited by admin on Mon Mar 31 17:47:32 GMT 2025
PRIMARY
ChEMBL
CHEMBL597
Created by admin on Mon Mar 31 17:47:32 GMT 2025 , Edited by admin on Mon Mar 31 17:47:32 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-604-6
Created by admin on Mon Mar 31 17:47:32 GMT 2025 , Edited by admin on Mon Mar 31 17:47:32 GMT 2025
PRIMARY
EPA CompTox
DTXSID60215315
Created by admin on Mon Mar 31 17:47:32 GMT 2025 , Edited by admin on Mon Mar 31 17:47:32 GMT 2025
PRIMARY
DRUG BANK
DBSALT000980
Created by admin on Mon Mar 31 17:47:32 GMT 2025 , Edited by admin on Mon Mar 31 17:47:32 GMT 2025
PRIMARY
EVMPD
SUB03769MIG
Created by admin on Mon Mar 31 17:47:32 GMT 2025 , Edited by admin on Mon Mar 31 17:47:32 GMT 2025
PRIMARY
MERCK INDEX
m8646
Created by admin on Mon Mar 31 17:47:32 GMT 2025 , Edited by admin on Mon Mar 31 17:47:32 GMT 2025
PRIMARY Merck Index
DAILYMED
Y7543E5K9T
Created by admin on Mon Mar 31 17:47:32 GMT 2025 , Edited by admin on Mon Mar 31 17:47:32 GMT 2025
PRIMARY
CAS
65-28-1
Created by admin on Mon Mar 31 17:47:32 GMT 2025 , Edited by admin on Mon Mar 31 17:47:32 GMT 2025
PRIMARY
FDA UNII
Y7543E5K9T
Created by admin on Mon Mar 31 17:47:32 GMT 2025 , Edited by admin on Mon Mar 31 17:47:32 GMT 2025
PRIMARY
RXCUI
227240
Created by admin on Mon Mar 31 17:47:32 GMT 2025 , Edited by admin on Mon Mar 31 17:47:32 GMT 2025
PRIMARY RxNorm
PUBCHEM
91430
Created by admin on Mon Mar 31 17:47:32 GMT 2025 , Edited by admin on Mon Mar 31 17:47:32 GMT 2025
PRIMARY
NCI_THESAURUS
C38691
Created by admin on Mon Mar 31 17:47:32 GMT 2025 , Edited by admin on Mon Mar 31 17:47:32 GMT 2025
PRIMARY
CHEBI
8081
Created by admin on Mon Mar 31 17:47:32 GMT 2025 , Edited by admin on Mon Mar 31 17:47:32 GMT 2025
PRIMARY
RS_ITEM_NUM
1530004
Created by admin on Mon Mar 31 17:47:32 GMT 2025 , Edited by admin on Mon Mar 31 17:47:32 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of PHENTOLAMINE
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966